Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
(YorkPedia Editorial):- Cambridge, Massachusetts Sep 17, 2023 (Issuewire.com) – Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to patient groups.
The Clinical Trials in Rare Diseases Conference. This event will explore the challenges in clinical trials for orphan drugs and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions. Topics at the conference include: the benefits of early planning and engagement with regulatory authorities, the importance of working closely with patients and patient advocacy groups, recruiting and retaining patients for rare disease studies.
More on YorkPedia:
- Explore the sites in San Antonio with help from Ocean Beach Travel
- Get Ready to Witness the Exclusive Blend of DUB-FUNK Vibes With KingZiLLa ft.BRO.BLAKE’s ‘Deadly Beginning’
- Enjoy Short Stays in Turkey with The Newly Improved Turkish eVisa
- Get a US Online Visa from Every Corner of the World
- Viviana Brignoni, DMD, a Periodontist with Beyond Periodontics, LLC
(YorkPedia Editorial):- Cambridge, Massachusetts Sep 17, 2023 (Issuewire.com) – Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to patient groups.
The Clinical Trials in Rare Diseases Conference. This event will explore the challenges in clinical trials for orphan drugs and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions. Topics at the conference include: the benefits of early planning and engagement with regulatory authorities, the importance of working closely with patients and patient advocacy groups, recruiting and retaining patients for rare disease studies.
This article was originally published by IssueWire. Read the original article here.
